A new study is raising questions about the long-term effects of popular diabetes and weight loss medications like Ozempic, and Wegovy. While these GLP-1 drugs have revolutionized the management of type 2 diabetes and obesity, research presented at the 2026 annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) suggests they may also silently weaken the musculoskeletal system.
Potential Risks to Bones and Joints
Researchers at Michigan State University analyzed the medical records of over 146,000 individuals to assess the long-term impact of GLP-1 receptor agonists. The analysis revealed a slightly increased risk of developing osteoporosis (+0.9%), gout (+0.8%), or osteomalacia (+0.1%) among those using semaglutide or liraglutide. Osteomalacia is a rare metabolic disease that causes bones to soften.
Several factors may explain these findings. Rapid and significant weight loss is known to set stress on the skeletal system. Quick fat loss can lead to a surge in uric acid levels in the blood, potentially triggering gout flare-ups. The medications, by suppressing appetite, could also contribute to nutritional deficiencies in calcium and vitamin D, both essential for bone health.
A Complex Picture Emerges
Despite these potential risks, the picture isn’t entirely negative. “We are just now reaching the point where long-term follow-up data is becoming available,” explained Muaaz Wajahath, the study’s lead author. Interestingly, other research indicates that patients taking GLP-1 medications may experience improved recovery after hip or knee replacement surgery, likely due to reduced mechanical stress on joints and better control of inflammation associated with osteoarthritis.
This dual effect – protective in some ways, potentially weakening in others – highlights the require for a careful assessment of the risks and benefits on an individual basis. Clinicians are now advised to closely monitor bone density in patients, particularly those with pre-existing risk factors for bone loss. The findings underscore the importance of understanding the systemic effects of these increasingly popular medications.
Personalized Prescriptions May Be Key
The goal isn’t to discourage the use of these medications, but to refine how they are prescribed. Given the relatively recent introduction of these drugs, our understanding of their broader health effects is still evolving. Beyond bone health, potential links have been suggested between GLP-1s and muscle loss or pancreatic issues.
“Any medication that sees such rapid adoption warrants thorough investigation,” Wajahath emphasized. Future efforts will focus on tailoring prescriptions to individual patients: if a patient is at risk for osteoporosis, increased monitoring or alternative therapies may be more appropriate. In the meantime, a nutrient-rich diet and regular physical activity remain the best ways to support bone health during weight loss treatment.
These research findings were presented at the 2026 annual meeting of the American Academy of Orthopaedic Surgeons (AAOS).
